Trinity Current Deferred Revenue from 2010 to 2024
| TRIB Stock | USD 1.12 0.01 0.88% |
Current Deferred Revenue | First Reported 2001-12-31 | Previous Quarter 50 K | Current Value 283 K | Quarterly Volatility 2.2 M |
Check Trinity Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Trinity Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Total Revenue of 78.6 M or Gross Profit of 35.1 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0095 or Days Sales Outstanding of 88.98. Trinity financial statements analysis is a perfect complement when working with Trinity Biotech Valuation or Volatility modules.
Trinity | Current Deferred Revenue |
Latest Trinity Biotech's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Trinity Biotech plc over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Trinity Biotech's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Trinity Biotech's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Trinity Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 846,701 | |
| Geometric Mean | 261,878 | |
| Coefficient Of Variation | 206.55 | |
| Mean Deviation | 1,135,682 | |
| Median | 224,000 | |
| Standard Deviation | 1,748,874 | |
| Sample Variance | 3.1T | |
| Range | 5.7M | |
| R-Value | (0.26) | |
| Mean Square Error | 3.1T | |
| R-Squared | 0.07 | |
| Significance | 0.34 | |
| Slope | (103,174) | |
| Total Sum of Squares | 42.8T |
Trinity Current Deferred Revenue History
About Trinity Biotech Financial Statements
Trinity Biotech stakeholders use historical fundamental indicators, such as Trinity Biotech's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Trinity Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Trinity Biotech's assets and liabilities are reflected in the revenues and expenses on Trinity Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Trinity Biotech plc. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 50 K | 47.5 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:Check out the analysis of Trinity Biotech Correlation against competitors. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (2.25) | Revenue Per Share 6.968 | Quarterly Revenue Growth 0.14 | Return On Assets (0.1) |
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.